Home » Stocks » ALRN

Aileron Therapeutics, Inc. (ALRN)

Stock Price: $1.94 USD -0.02 (-1.02%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $1.96 +0.02 (1.03%) Jan 20, 7:52 PM
Market Cap 156.77M
Revenue (ttm) n/a
Net Income (ttm) -23.40M
Shares Out 39.32M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $1.94
Previous Close $1.96
Change ($) -0.02
Change (%) -1.02%
Day's Open 2.00
Day's Range 1.83 - 2.00
Day's Volume 3,448,253
52-Week Range 0.29 - 2.29

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

-- Several existing Aileron investors, including Satter Medical Technology Partners  and Lincoln Park Capital Fund, LLC, also participated in the offering -- – Aileron plans to use net proceed...

GlobeNewsWire - 2 weeks ago

WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare invest...

InvestorPlace - 2 weeks ago

As with many biopharma names, there's volatility and risk in ALRN stock. This firm is seeking to reduce the effects of chemotherapy.

GlobeNewsWire - 2 months ago

WATERTOWN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the third quarter ended September 30, 2020.

GlobeNewsWire - 2 months ago

WATERTOWN, Mass., Oct. 24, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced new positive clinical data from its ongoing Phase 1b trial demonstrating clinical proof ...

GlobeNewsWire - 3 months ago

WATERTOWN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference call and live webcast to discuss results from a Phase 1b ...

Zacks Investment Research - 3 months ago

Aileron Therapeutics (ALRN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 3 months ago

WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that proof-of-concept data from the company’s Phase 1b study of ALRN-6924 will be featur...

GlobeNewsWire - 3 months ago

WATERTOWN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) f...

GlobeNewsWire - 4 months ago

WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a co...

Zacks Investment Research - 4 months ago

Here we discuss five biotech companies recording impressive growth so far in 2020.

Other stocks mentioned: CLDX, EBS, HZNP, NVAX
GlobeNewsWire - 5 months ago

WATERTOWN, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the second quarter ended June 30, 2020.

GlobeNewsWire - 5 months ago

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participat...

GlobeNewsWire - 5 months ago

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today that it has completed enrollment in the dose optimization expansion cohort of its ongoi...

GlobeNewsWire - 6 months ago

 -- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy’s off-target effects -- ...

GlobeNewsWire - 7 months ago

WATERTOWN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exe...

GlobeNewsWire - 7 months ago

WATERTOWN, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock...

GlobeNewsWire - 7 months ago

WATERTOWN, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. A...

Zacks Investment Research - 7 months ago

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

Other stocks mentioned: CBAY, EFOI, MRSN, MVIS
GlobeNewsWire - 7 months ago

WATERTOWN, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 ...

GlobeNewsWire - 8 months ago

Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients - - - Scheduled to report interim res...

GlobeNewsWire - 8 months ago

Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study - - -  Final data readout from Phase 1b for both dose optimization and schedule optim...

GlobeNewsWire - 1 year ago

WATERTOWN, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the p...

Seeking Alpha - 1 year ago

Aileron Therapeutics, Inc. (ALRN) CEO Manuel Aivado on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy

GlobeNewsWire - 1 year ago

Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy.

GlobeNewsWire - 1 year ago

Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer.

GlobeNewsWire - 1 year ago

Final data expected in the second quarter of 2020 Final data expected in the second quarter of 2020

GlobeNewsWire - 1 year ago

WATERTOWN, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patien...

GlobeNewsWire - 1 year ago

WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and ot...

About ALRN

Aileron Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myel... [Read more...]

Industry
Biotechnology
IPO Date
Jun 29, 2017
CEO
Dr. Manuel C. Aivado
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
ALRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ALRN stock is "Strong Buy." The 12-month stock price forecast is 4.00, which is an increase of 106.19% from the latest price.

Price Target
$4.00
(106.19% upside)
Analyst Consensus: Strong Buy